Literature DB >> 25940556

The effect of prophylactic topical antibiotics on bacterial resistance patterns in endophthalmitis following intravitreal injection.

Philip Storey1,2, Michael Dollin3, Nadim Rayess3, John Pitcher3, Sahitya Reddy4, James Vander3, Jason Hsu3, Sunir Garg5.   

Abstract

PURPOSE: The purpose of this study was to evaluate the effect of prophylactic topical antibiotics on bacterial resistance patterns in endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor (VEGF) medications.
METHODS: In this retrospective case-control study, billing records and an infection log were used to identify all cases of endophthalmitis following intravitreal injection of ranibizumab, bevacizumab, or aflibercept between January 1, 2009 and September 30, 2013 at a single retina practice. A 28-month period when topical antibiotic drops were prescribed for use four times a day for 4 days following intravitreal injection was compared to a 21-month period when topical antibiotics were not prescribed. Patients treated during an 8-month transition period were excluded as prescription practices were changed.
RESULTS: During the study period, a total of 172,096 anti-VEGF injections were performed. During the period when antibiotics were prescribed, 28 cases of suspected infectious endophthalmitis occurred from a total of 57,654 injections, ten of which were culture-positive. During the period when antibiotics were not used, 24 cases of suspected endophthalmitis occurred from a total of 89,825 injections, six of which were culture-positive. During the antibiotic period, four of the ten (40 %) culture-positive cases grew bacteria resistant to the prescribed prophylactic antibiotics. In contrast, none of the six culture-positive cases grew bacteria resistant to those antibiotics during the period when antibiotics were not used (odds ratio = 9.0; 95 % confidence interval = 0.40-203.3; p = 0.17).
CONCLUSIONS: The use of prophylactic topical antibiotics following intravitreal injection may lead to higher rates of antibiotic-resistant bacteria in culture-positive endophthalmitis cases.

Entities:  

Keywords:  Antibiotics; Endophthalmitis; Intravitreal injection; Prophylaxis; Resistance

Mesh:

Substances:

Year:  2015        PMID: 25940556     DOI: 10.1007/s00417-015-3035-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  23 in total

Review 1.  Mutation frequencies and antibiotic resistance.

Authors:  J L Martinez; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

2.  Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection.

Authors:  Eugene Milder; James Vander; Chirag Shah; Sunir Garg
Journal:  Ophthalmology       Date:  2012-03-13       Impact factor: 12.079

3.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  Antibiotic susceptibility of preoperative normal conjunctival bacteria.

Authors:  Herminia Miño de Kaspar; Michael J Koss; Lingmin He; Mark S Blumenkranz; Christopher N Ta
Journal:  Am J Ophthalmol       Date:  2005-04       Impact factor: 5.258

5.  Bacterial dispersal associated with speech in the setting of intravitreous injections.

Authors:  Joanne C Wen; Colin A McCannel; A Brian Mochon; Omai B Garner
Journal:  Arch Ophthalmol       Date:  2011-08-08

6.  Antibiotic resistance of conjunctiva and nasopharynx evaluation study: a prospective study of patients undergoing intravitreal injections.

Authors:  Stephen J Kim; Hassanain S Toma; Narinder K Midha; Edward F Cherney; Franco M Recchia; Terrence J Doherty
Journal:  Ophthalmology       Date:  2010-07-24       Impact factor: 12.079

7.  Intravitreal injections: is there benefit for a theatre setting?

Authors:  Robin G Abell; Nathan M Kerr; Penelope Allen; Brendan J Vote
Journal:  Br J Ophthalmol       Date:  2012-09-27       Impact factor: 4.638

8.  Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies.

Authors:  Colin A McCannel
Journal:  Retina       Date:  2011-04       Impact factor: 4.256

9.  Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous.

Authors:  Seenu M Hariprasad; Kevin J Blinder; Gaurav K Shah; Rajendra S Apte; Brett Rosenblatt; Nancy M Holekamp; Matthew A Thomas; William F Mieler; Jingduan Chi; Randall A Prince
Journal:  Arch Ophthalmol       Date:  2005-01

10.  Antibiotic resistance patterns of ocular bacterial flora: a prospective study of patients undergoing anterior segment surgery.

Authors:  Christopher N Ta; Robert T Chang; Kuldev Singh; Peter R Egbert; Erin M Shriver; Mark S Blumenkranz; Herminia Miño de Kaspar
Journal:  Ophthalmology       Date:  2003-10       Impact factor: 12.079

View more
  15 in total

1.  Antibiotic prophylaxis for preventing endophthalmitis after intravitreal injection: a systematic review.

Authors:  Francesca Menchini; Giacomo Toneatto; Alba Miele; Simone Donati; Paolo Lanzetta; Gianni Virgili
Journal:  Eye (Lond)       Date:  2018-06-11       Impact factor: 3.775

2.  Culture-Proven Endophthalmitis After Intravitreal Injection: A 10-Year Analysis.

Authors:  Joseph M Simonett; Austin Igelman; Stanford C Taylor; J Peter Campbell; Thomas S Hwang; Phoebe Lin; Andreas K Lauer; Christina J Flaxel
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2019-01-01       Impact factor: 1.300

3.  Intracameral Antibiotics in the Shadow of Hemorrhagic Occlusive Retinal Vasculitis.

Authors:  Ayman Naseri; Ronald B Melles; Neal H Shorstein
Journal:  Ophthalmology       Date:  2017-05       Impact factor: 12.079

4.  Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms.

Authors:  Mira M Sachdeva; Ala Moshiri; Henry A Leder; Adrienne W Scott
Journal:  J Ophthalmic Inflamm Infect       Date:  2016-01-12

5.  Exogenous Streptococcus pneumoniae Endophthalmitis in Diabetic Rabbits.

Authors:  Angela H Benton; Linda K Fulton; Mary E Marquart
Journal:  Sci Rep       Date:  2017-04-07       Impact factor: 4.379

6.  Intravitreal injections of anti-VEGF agents and antibiotic prophylaxis for endophthalmitis: A systematic review and meta-analysis.

Authors:  Manuel F Bande; Raquel Mansilla; María P Pata; Maribel Fernández; María José Blanco-Teijeiro; Antonio Piñeiro; Francisco Gómez-Ulla
Journal:  Sci Rep       Date:  2017-12-22       Impact factor: 4.379

7.  Incidence of Endophthalmitis after Intravitreal Anti-Vascular Endothelial Growth Factor Injections in an Operating Room in China.

Authors:  Yanyun Chen; Wenbin Wei; Demetrios G Vavvas; Feng Zhang; Haicheng She; Haiying Zhou; Lei Li; Yao Huang; Dimitrios P Ntentakis; Xiangyu Shi
Journal:  J Ophthalmol       Date:  2020-11-12       Impact factor: 1.909

8.  Survey of Intravitreal Injection Techniques Among Retina Specialists in Mexico.

Authors:  Andree Henaine-Berra; Vanesa Flores-Peredo; Gabriela Lopezcarasa-Hernandez; Maria Ana Martinez-Castellanos; Ximena Mira-Lorenzo; Adriana Solis-Vivanco; Gerardo Garcia-Aguirre
Journal:  Clin Ophthalmol       Date:  2020-11-26

9.  Drug-resistant coagulase-negative staphylococcal endophthalmitis following dexamethasone intravitreal implant.

Authors:  Prabhushanker Mahalingam; Tasneem Tameem Topiwalla; Geetha Ganesan
Journal:  Indian J Ophthalmol       Date:  2017-07       Impact factor: 1.848

10.  Intravitreal Injections with Vascular Endothelial Growth Factor Inhibitors: A Practical Approach.

Authors:  Anne-Sofie Petri; Kirstine Boysen; Lasse J Cehofski; Elon H C van Dijk; Chantal Dysli; Josefine Fuchs; Rodolfo Mastropasqua; Yousif Subhi
Journal:  Ophthalmol Ther       Date:  2020-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.